Document:

Amended and Restated 2008 Board of Directors Compensation Plan

 EXHIBIT 10.1 
 FiberNet Telecom Group, Inc. 
 Amended and Restated 2008 Board of Directors Compensation Plan 

 (as adopted on and as of July 29, 2008) 
  

	I.	Board of Directors 

  

	 	A.	$16,000 base salary, payable in cash on a quarterly basis in arrears 

  

	 	B.	$1,000 payable in cash for each meeting attended 

  

	 	C.	Additional $500 payable in cash to the Board Chairman for each meeting attended 

  

	 	D.	Additional $10,000 per annum, payable in cash on a quarterly basis in arrears to the Board Chairman 

  

	II.	Audit Committee 

  

	 	A.	$1,000 payable in cash for each meeting attended 

  

	 	B.	Additional $500 payable in cash to the Committee Chairman for each meeting attended 

  

	 	C.	Additional $10,000 per annum, payable in cash on a quarterly basis in arrears to the Committee Chairman 

  

	III.	Compensation Committee 

  

	 	A.	$1,000 payable in cash for each meeting 

  

	 	B.	Additional $500 payable in cash to the Committee Chairman for each meeting attended 

  

	IV.	Nominating and Governance Committee 

  

	 	A.	$1,000 payable in cash for each meeting attended 

  

	 	B.	Additional $500 payable in cash to the Committee Chairman for each meeting attended 

	V.	Per Diem for Special Projects 

  

	 	A.	The Chief Executive Officer or Chief Financial Officer of the company may request that a director provide advisory services on a project-specific basis. 

  

	 	B.	Directors will be compensated for undertaking any such services at a rate of $1,000 per day. The company will pro rate the per diem fee as appropriate. For example, if a director
were to take part in a two-hour conference call at the request of the Chief Executive Officer or Chief Financial Officer, then such director would be compensated with a payment of $250 (i.e., two hours equal 25% of a standard eight-hour day, and
$250 is 25% of $1,000). Compensation for such services will be paid in cash on a monthly basis in arrears. 

  

	 	C.	Directors who sit on the Audit Committee are expressly prohibited from providing such services to the company. Further, independent directors who do not sit on the Audit Committee
may be compensated up to a maximum of $60,000 in connection with providing these services to the company. The company has established the foregoing limitations in order to ensure compliance with the independence requirements under applicable NASD
Marketplace Rules and Securities Exchange Act regulations of the SEC. 

  

	VI.	General 

  

	 	A.	Compensation is payable only to non-employee directors. 

  

	 	B.	Directors may have their reasonable, documented travel expenses reimbursed by the company. 

  

	 	C.	The compensation to be paid under this Plan is payable only with respect to meetings actually held, whether scheduled in advance or otherwise, and does not apply to other actions
taken by directors outside of the context of a meeting (such as the execution of a written consent in lieu of a meeting). Compensation for meetings will be paid in cash on a quarterly basis in arrears.First Amendment dated May 31, 2008 to Lease Agreement

 Exhibit 10.1 
 FIRST AMENDMENT TO LEASE 
 THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is
made as of May 31, 2008, by and between ARE-SAN FRANCISCO NO. 12, LLC, a Delaware limited liability company (“Landlord”), and EXELIXIS, INC., a Delaware corporation (“Tenant”). 
 RECITALS 
 A. Landlord and
Tenant entered into that certain Lease Agreement dated as of September 14, 2007 (the “Lease”). Pursuant to the Lease, Tenant leases certain premises consisting of approximately 66,000 rentable square feet
(“Premises”) in a building located at 249 East Grand Avenue, South San Francisco, California. The Premises are more particularly described in the Lease. Capitalized terms used herein without definition shall have the meanings
defined for such terms in the Lease. 
 B. Landlord has caused the Premises to be re-measured pursuant to Section 6 of the
Lease and determined, pursuant to such re-measurement, that the Premises is approximately 71,746 rentable square feet and that the Building is 129,501 rentable square feet. 
 C. Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the Lease to, revise the definitions of Premises,
Rentable Area of the Premises, Rentable Area of Building, Rentable Area of Project and Tenant’s Share of the Building to reflect the rentable square footage of the Premises and the Building as re-measured.  
 NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions
contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: 
  

	1.	Premises. The defined term “Premises” on page 1 of the Lease is hereby deleted in its entirety and replaced with the following:

 “Premises: The third and fourth floor of the Building, containing approximately 68,738 rentable
square feet and the server room on the first floor of the Building, containing approximately 3,008 rentable square feet, all as shown on Exhibit A, together with the non-exclusive right to use the Common Areas, including, without limitation,
the Building’s loading dock.” 
  

	2.	Rentable Area of Premises. The defined term “Rentable Area of Premises” on page 1 of the Lease is hereby deleted in its entirety and replaced with the
following: 

 “Rentable Area of Premises: 71,746 sq. ft.” 
  

	3.	Rentable Area of Building. The defined term “Rentable Area of Building” on page 1 of the Lease is hereby deleted in its entirety and replaced
with the following: 

 “Rentable Area of Building: 129,501 sq. ft.” 
  

	4.	Rentable Area of Project. The defined term “Rentable Area of Project” on page 1 of the Lease is hereby deleted in its entirety and replaced with the
following: 

 “Rentable Area of Project: 129,501 sq. ft., subject to adjustment as provided for in
Section 6 hereof.” 
 

 

	5.	Tenant’s Share of the Building. The defined term “Tenant’s Share of the Building” on page 1 of the Lease is hereby deleted in its entirety
and replaced with the following: 

 “Tenant’s Share of the Building: 55.40%” 

 

	6.	Miscellaneous. 

 a. This First Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This First Amendment may be
amended only by an agreement in writing, signed by the parties hereto. 
 b. This First Amendment is binding upon and shall inure to
the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders. 
 c. This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which when taken
together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other counterpart
identical thereto except having additional signature pages executed by other parties to this First Amendment attached thereto. 
 d.
Except as amended and/or modified by this First Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this First Amendment. In the event of any
conflict between the provisions of this First Amendment and the provisions of the Lease, the provisions of this First Amendment shall prevail. Whether or not specifically amended by this First Amendment, all of the terms and provisions of the Lease
are hereby amended to the extent necessary to give effect to the purpose and intent of this First Amendment. 
 [Signatures are on the next
page.] 
 

 

 IN WITNESS WHEREOF, the parties hereto have executed this First Amendment as of the day and year
first above written. 
  

													
	LANDLORD:	 		 	ARE-SAN FRANCISCO NO. 12, LLC,
a Delaware limited liability company.
				
		 		 	By:	 	ALEXANDRIA REAL ESTATE EQUITIES, L.P., a Delaware limited partnership, managing member
					
		 		 		 	By:	 	ARE-QRS CORP.,
a Maryland Corporation,
general partner
							
		 		 		 		 		 	By:	 	/s/ Eric S. Johnson
		 		 		 		 		 	Its:	 	Assistant Vice President
Real Estate Legal Affairs

  

									
	TENANT:	 		 	EXELIXIS, INC.,
a Delaware corporation
					
		 		 		 	By:	 	/s/ George A. Scangos
		 		 		 	Its:	 	President and Chief Executive OfficerSecond Amendment to the Product Development and Commercialization Agreement

 Exhibit 10.3 
 EXECUTION 
 SECOND AMENDMENT TO THE PRODUCT DEVELOPMENT AND 
 COMMERCIALIZATION AGREEMENT BETWEEN SMITHKLINE BEECHAM 
 CORPORATION D/B/A
GLAXOSMITHKLINE AND EXELIXIS, INC. DATED 
 AS OF OCTOBER 28, 2002. 
 This SECOND AMENDMENT (the “Second Amendment”) is entered into as of June 13,
2008 (the “Second Amendment Effective Date”), by and between SMITHKLINE BEECHAM CORPORATION, a Pennsylvania corporation, doing business as GlaxoSmithKline
(“GSK”), and EXELIXIS, INC., a Delaware corporation (“EXEL”). EXEL and GSK are each referred to herein individually as a “Party” or, collectively, as the
“Parties.” 
 RECITALS 
 WHEREAS, the Parties entered into that certain Product Development and Commercialization Agreement dated as of October 28, 2002, and as amended by the Parties on
January 10, 2005 (collectively, the “Development Agreement”) under which EXEL and GSK formed a broad alliance to discover, develop and commercialize novel therapeutics; and 
 WHEREAS, the Parties now desire to amend certain provisions of the Development Agreement as set forth below in this
Second Amendment. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein
contain, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
 AGREEMENT 
  

	1.	AMENDMENT OF THE DEVELOPMENT AGREEMENT 

 The Parties hereby agree to amend the terms of the Development Agreement as provided below, effective as of the Second Amendment Effective Date. To the
extent that the Development Agreement is explicitly amended by this Second Amendment, the terms of this Second Amendment will control where the terms of the Development Agreement are contrary to or conflict with the following provisions. Where the
Development Agreement is not explicitly amended, the terms of the Development Agreement will remain in full force and effect. Capitalized terms used in this Second Amendment that are not otherwise defined herein shall have the same meanings as such
terms are defined in the Development Agreement. 
 1.1 Amendment of Section 1.29. Section 1.29 is hereby deleted in
its entirety and replaced with the following: 
 “1.29 [Intentionally left blank.]” 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 1.2 Amendment of Section 1.94. Section 1.94 is hereby deleted in its entirety and
replaced with the following: 
 “1.94 [Intentionally left blank.]” 
 1.3 Amendment of Section 1.118. Section 1.118 is hereby deleted in its entirety and replaced with the following: 
 “1.118 “Product” shall mean, [ * ].” 
 1.4 Amendment of Section 3.9. Section 3.9 is hereby deleted in its entirety and replaced with the following: 
 3.9 Future Acquired Technology. [ * ]. 
 1.5 Amendment of Section 5.4. Section 5.4 is hereby deleted in its entirety and replaced with the following: 
 “5.4. [Intentionally left blank.]” 
 1.6 Amendment of Section 5.5.1. Section 5.5.1 is hereby deleted in its entirety and replaced with the following: 
 “5.5.1 Termination of Development by GSK. In the event that GSK exercises its Development Election and accepts a particular Licensed Product into the Commercialization Program and thereafter[ * ].”

 1.7 Amendment of Section 6.3.2. Section 6.3.2 is hereby deleted in its entirety and replaced with the following:

 “6.3.2. [Intentionally left blank.] 
 1.8 Amendment of Section 7.1.1. Section 7.1.1 is hereby deleted in its entirety and replaced with the following: 
 “7.1.1 Regarding Targets and Compounds. Except as necessary to perform its obligations under this Agreement, EXEL shall not, either alone, through an Affiliate or with any Third Party: 
  

	 	(a)	during [ * ]; 

  

	 	(b)	during [ * ]; and 

  

	 	(c)	[Intentionally left blank.] 

  

	 	(d)	During [ * ].” 

 1.9 Amendment of
Section 13.1.1. Section 13.1.1 is hereby deleted in its entirety and replaced with the following: 
 “13.1.1 Automatic Effect. In all cases hereunder, regardless of whether GSK elects to terminate this Agreement or not, in accordance with Section 13.1.2, effective [ * ] the consummation of such Subject Transaction:[ *
].” 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 1.10 Amendment of Section 13.1.2. Section 13.1.2 is hereby deleted in its
entirety and replaced with the following: 
 “13.1.2 GSK Right to Terminate. In the event that such Subject
Transaction occurs prior to the expiration of the Development Term, or the Extension Period, if any, then GSK shall have the right, upon written notice to EXEL within [ * ] of the consummation of such Change of Control, to terminate this Agreement.
In the event GSK so elects to terminate this Agreement:[ * ].” 
 1.11 Amendment of Section 13.2.1.
Section 13.2.1 is hereby deleted in its entirety and replaced with the following: 
 “13.2.1 Automatic
Effect. Effective [ * ] the consummation of such Subject Transaction:[ * ].” 
 1.12 Deletion of Exhibit 7.1.1(c).
Exhibit 7.1.1(c) is hereby deleted in its entirety. 
  

	2.	MISCELLANEOUS 

 2.1 Full
Force and Effect. This Second Amendment amends the terms of the Development Agreement and is deemed incorporated into, and governed by all other terms of, the Development Agreement. The provisions of the Development Agreement, as amended by this
Second Amendment, remain in full force and effect. 
 2.2 Further Actions. Each Party shall execute, acknowledge and deliver
such further instruments, and do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Second Amendment. 
 2.3 Counterparts. This Second Amendment may be signed in counterparts, each and every one of which shall be deemed an original, notwithstanding variations in format or file designation, which may result
from the electronic transmission, storage and printing of copies of this Second Amendment from separate computers or printers. Facsimile signatures shall be treated as original signatures. 
 Signature Page Follows 
 [ * ] = Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 IN WITNESS WHEREOF, the Parties have
caused this Second Amendment to be executed by their duly authorized representatives as of the Second Amendment Effective Date. 
  

									
	EXELIXIS, INC.	 		 	SMITHKLINE BEECHAM CORPORATION
					
	By:	 	/s/ George Scangos, Ph.D.	 		 	By:	 	/s/ Carol G. Ashe
	Print Name:	 	George Scangos, Ph.D.	 		 	Print Name:	 	Carol G. Ashe
	Title:	 	President & C.E.O.	 		 	Title:	 	Vice President & Secretary

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]